At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Pooja Ghatalia, MD, of Fox Chase Cancer Center, and Amanda Nizam, MD, of Cleveland Clinic, break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC
By Pooja Ghatalia, MD, Amanda Nizam, MD - Last Updated: February 20, 2025Related Posts
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.